gfp,
It's not an easy call. If we all had crystal balls--for predicting, not for fornicating--we probably wouldn't be bothered with message boards, and you'd have your money in something other than a CD.
I own alot of GNVC. They lost their CFO AND their CMO in the space of a short time, just a number of months ago. The stock dropped to about $.90/share. The CEO replaced the two guys with two very excellent hires, upgrades over the guys who left. The news today on GNVC was very good--better than the Market is treating it--and the stock is close to doubling off the lows. They're certainly not out of the water--they need to do a financing (Hey, so what else is new in microcap biotech?), but they're not dead either.
Stoll didn't sound like a guy ready to throw in the towel. Let's see where Mansbach winds up and, far more importantly, who Stoll gets to replace him. The emphasis on high-impacts now would seem to place a premium on Varney's stewardship, so let's see what Stoll/Varney have in mind. (Now if Varney decides to leave, then even Neuro might throw in the towel.) But this announcement, coming as it does right before the financing, doesn't help matters.
Bladerunner
News 
Market Data 
Discover 
AI
